Journal of Clinical Oncology
Articles in this Issue
Stop cancelling surgery for esophageal cancer: An analysis of treatment-related mortality in 60,000 patients.
e16102 Background: The optimal management of squamous cell carcinoma (SCC) of the esophagus remains controversial. There is a growing perception that defi...
Biomarker testing of lung cancer in North America versus globally.
8541 Background: Biomarker testing is essential to optimize lung cancer (LC) care, yet uptake of testing is suboptimal due to lack of access, cost, and lo...
A nationwide survey of gaps in oncology residency education in Armenia and the potential role of journal clubs.
e21024 Background: In Armenia, oncology residency programs mainly focus on clinical skills, resulting in limited opportunities for structured research tra...
Patient-reported outcomes, race, and ethnicity in high-impact lung cancer clinical trials.
e23015 Background: Lung cancer clinical trials enroll disproportionately low numbers of Black and Hispanic patients. Patient-reported outcomes (PRO) accur...
Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment.
e16170 Background: Advanced hepatocellular carcinoma (HCC) has a robust array of first-line treatment options, including various targeted therapies and im...
Socioeconomic and clinical predictors of 30-day readmissions in AML patients undergoing allogeneic stem cell transplantation.
6548 Background: 30-day readmissions among acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) are a key...
CCDI-COG molecular characterization initiative: The expanding data on childhood cancer.
10013 Background: The Molecular Characterization Initiative (MCI), a collaboration between the Children's Oncology Group (COG) and the NCIs Childhood Canc...
Sociodemographic and clinical determinants of survival in metastatic breast cancer: A population-based analysis from a Latin American developing country.
e13125 Background: To evaluate the impact of tumor, treatment, and sociodemographic factors on overall survival (OS) and cancer-specific survival (CSS) in...
First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).
8521 Background: 1L anti–PD-(L)1 antibodies ± chemotherapy are standard of care for patients (pts) with a/mNSCLC without a...
Accuracy of early detection of pancreatic cancer using cfDNA methylation marker <i>ZFP30</i> .
e16460 Background: Pancreatic cancer (PC) is one of the deadliest malignancies, largely due to the lack of effective early detection methods. Traditional...
The difference in the odds of development of bleomycin pulmonary toxicity in patients with germ cell tumors and Hodgkin’s lymphoma receiving granulocyte colony-stimulating factor alongside bleomycin based regimens: Systematic review and meta-analysis.
e17015 Background: Bleomycin-induced pulmonary toxicity (BPT) is a severe adverse effect that is related to the administration of bleomycin. It increases...
Preclinical in vitro and in vivo evaluation of novel ANXV-chemo protein drug conjugate against human triple-negative breast cancer.
e15016 Background: The elevated nonapoptotic exposure of the phospholipid phosphatidylserine (PS) on cancer cells and tumor vasculature provides a unique...
NGS testing for patient selection in left-sided RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy.
e15565 Background: RAS/BRAF polymerase chain reaction (PCR)-testing is currently used for the selection of monoclonal antibody for patients (pts) with lef...
Descriptive analysis of the PCP-ONC CARES Program: Integrating primary care into oncology in a value-based system.
e13865 Background: Survivorship care is a critical component of oncology, yet many systems lack comprehensive models addressing the needs of patients acro...
Real-world treatment patterns, sequences, and outcomes in patients with mCRPC in US urology clinics.
e17069 Background: Managing community-based patients with mCRPC is challenging due to varied treatment and sequencing strategies, which impact clinical ou...
Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial.
7532 Background: Lenalidomide (LEN), bortezomib (BORT), and dexamethasone (DEX) are recommended for NDMM. Iberdomide (IBER), an oral CELMoD agent, has str...
Evolving trends in Latin American oncology clinical trial sites.
e23155 Background: The globalization of oncology trials has created opportunities for emerging regions to play larger roles in clinical research. This stu...
Machine-learning (ML) model predictive for chemotherapy toxicity and termination in a real-world community oncology practice.
e13697 Background: Randomized clinical trials involve carefully selected patient (pts) to develop new therapeutic indications. However, effectiveness in r...
Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy.
e16151 Background: Neoadjuvant immunotherapy combined with chemotherapy followed by surgery (NICT+S) has shown favorable pathological complete response (p...
A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
5042 Background: Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in metastatic castration-resistant prostate cancer (mCRPC), and is linked...
The impact of opioid use prior to pancreatic cancer diagnosis on overall survival: Insights from SEER-Medicare data.
e16424 Background: Pancreatic cancer has a poor prognosis, with a 5-year survival rate of only 9%. Pain is one of the most common symptoms, often requirin...
Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.
8530 Background: MTAP-cooperative PRMT5 inhibitors are under development for MTAP-loss solid tumors. However, clinical, genomic, and pathological features...
Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had <i>TP53</i> mutations in the SYMPATICO study.
7017 Background: The phase 3 SYMPATICO study evaluated ibrutinib (Ibr) combined with venetoclax (Ven) in 3 cohorts of patients (pts) with MCL: an open-lab...
Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer.
2634 Background: Immune checkpoint inhibitor (ICI)-based therapy is currently the first-line treatment for patients with lung adenocarcinoma (LUAD) and lu...
Key predictors of peritonitis in ovarian cancer hospitalizations: Insights for early intervention.
e17603 Background: Malignant ascites is a common complication of advanced ovarian cancer (OC) due to peritoneal metastasis, occurring in over one-third of...